Bacterial vaginosis (BV) is a common vaginal disorder characterized by the decrease of lactobacilli and overgrowth of Gardnerella vaginalis and resident anaerobic vaginal bacteria. In the present work, the effects of rifaximin vaginal tablets on vaginal microbiota and metabolome of women affected by BV were investigated by combining quantitative PCR and a metabolomic approach based on 1 H nuclear magnetic resonance. To highlight the general trends of the bacterial communities and metabolomic profiles in response to the antibiotic/placebo therapy, a multivariate statistical strategy was set up based on the trajectories traced by vaginal samples in a principal component analysis space. Our data demonstrated the efficacy of rifaximin in restoring a health-like condition in terms of both bacterial communities and metabolomic features. In particular, rifaximin treatment was significantly associated with an increase in the lactobacillus/BV-related bacteria ratio, as well as with an increase in lactic acid concentration and a decrease of a pool of metabolites typically produced by BV-related bacteria (acetic acid, succinate, shortchain fatty acids, and biogenic amines). Among the tested dosages of rifaximin (100 and 25 mg for 5 days and 100 mg for 2 days), 25 mg for 5 days was found to be the most effective.
Bacterial vaginosis (BV) is a complex polymicrobial vaginal disorder associated with an increase in the taxonomic richness and diversity of the vaginal microbiota. BV is microbiologically characterized by replacement of the lactobacillus-predominant vaginal microbiota by potential pathogenic anaerobic bacteria (1, 2). The diagnosis of BV is based on Amsel's criteria (1) and Nugent score determinations (3). The current recommended treatment of BV includes metronidazole (oral or vaginal) or clindamycin (vaginal) (4); however, the short-term (30 days) cure rate is often poor, and recurrences are common (5, 6).Rifaximin is a new candidate for the local treatment of BV thanks to its antibacterial activity, which covers Gardnerella vaginalis and other pathogens responsible for urogenital infections (7,8). Rifaximin is a semisynthetic rifamycin derivative characterized by low systemic absorption and good antibacterial activity. In common with the structural analogue rifampin and other members of the rifamycin class, it acts on the  subunit of the bacterial RNA polymerase to inhibit RNA synthesis (9, 10). Recently, the efficacy of rifaximin vaginal tablets in the treatment of BV was demonstrated by evaluating the rate of clinical remission (11) and the restoration of normal vaginal communities (12) and proteome profiles (13).BV, as well as antibiotics used for the treatment of this disturbance, cause perturbations of the vaginal ecosystem, which are reflected in the overall profile of the metabolites produced by the host-bacterium metaorganism. The study of the comprehensive modifications occurring in the metabolic profiles of living systems actually represents the main field of metabolomics. Metabolomics is, by definitio...